Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Pfizer’s experimental lung cancer drug sigvotatug vedotin has failed to meet its primary objective in a late-stage clinical trial.
📍 The outcome
Pfizer’s experimental drug **sigvotatug vedotin** failed to meet the primary endpoint in its Phase 3 trial for previously treated metastatic non-squamous non-small cell lung cancer. The results prompted a stock reaction and marked the first setback for a new antibody-drug conjugate developed from Pfizer’s acquisition of Seagen.
Epilogue added 44d ago, after coverage quieted.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Where it stands
Pfizer has reported topline results from a Phase 3 study of sigvotatug vedotin, an antibody-drug conjugate (ADC) designed to treat patients with previously treated metastatic non-squamous non-small cell lung cancer (NSCLC). The drug did not reach the trial's main goal.
Coverage from Reuters, Yahoo Finance, STAT, Fierce Biotech, and Business Wire emphasizes that this medication was the first new ADC to reach clinical trials following Pfizer's acquisition of Seagen. Market reports indicate that Pfizer stock is reacting to these mixed results.
Future developments remain dependent on further company disclosures. Coverage does not yet specify the next steps for the sigvotatug vedotin program or the potential implications for other pipeline assets.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 44d ago.
Who reported it (5)
- Pfizer's experimental drug misses main goal of lung cancer trial Reuters · 47d ago
- PFE Stock Reacts To Mixed Topline Results For Seagen-Origin Cancer Drug Yahoo Finance · 47d ago
- Closely watched Pfizer lung cancer drug falls short in clinical trial statnews.com · 47d ago
- Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial Fierce Biotech · 47d ago
- Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer Business Wire · 47d ago
Answered
What is sigvotatug vedotin?
It is an experimental antibody-drug conjugate originating from the Seagen acquisition, developed for use in non-squamous non-small cell lung cancer.
Did the drug meet its trial goals?
No, coverage states the drug missed its primary endpoint in the Phase 3 clinical trial.
What is the status of the drug's development?
Coverage confirms the trial results are topline, but provides no further details on current program status.
Topics
Related trends
First person gets new experimental vaccine for Ebola
The first human participant has received an experimental vaccine targeting the Bundibugyo ebolavirus strain as clinical trials launch in the DRC.
Exclusive: A couple paid more than $800,000 for a gene-editing therapy for their daughter. She died, and it wasn’t made public
A report reveals the death of a 6-year-old child following an experimental gene-editing treatment in China that was not disclosed to the public.
Non-smokers under 50 are getting lung cancer. What they eat raised a red flag
Medical reports are highlighting an emerging trend of lung cancer diagnoses in non-smokers under 50, with researchers focusing on potential dietary links.
Kalshi Will Offer Sports-Style Betting on Drug Trial Results
Kalshi has introduced new prediction markets that allow users to place wagers on the outcomes of clinical trials and pending FDA drug decisions.
Former smokers who vape face higher lung cancer and death risks, study finds
New research suggests that former smokers who utilize e-cigarettes may encounter elevated risks for lung cancer and mortality.
An experimental Alzheimer's drug shows some promise as researchers hunt new approaches
Biogen’s experimental tau-targeting drug, diranersen, has triggered market volatility following the release of mixed clinical trial data.